Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV000774590 | SCV000908354 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-08-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001856091 | SCV002190947 | benign | Hereditary nonpolyposis colorectal neoplasms | 2023-07-17 | criteria provided, single submitter | clinical testing | |
Gene |
RCV002285413 | SCV002576044 | uncertain significance | not provided | 2023-04-10 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 21437237) |
Ambry Genetics | RCV000774590 | SCV002667793 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-03-26 | criteria provided, single submitter | clinical testing | The p.E221K variant (also known as c.661G>A), located in coding exon 4 of the MSH6 gene, results from a G to A substitution at nucleotide position 661. The glutamic acid at codon 221 is replaced by lysine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Baylor Genetics | RCV004569455 | SCV005054966 | uncertain significance | Endometrial carcinoma | 2024-01-15 | criteria provided, single submitter | clinical testing |